7 Hubert Street
15 articles with Celmatix, Inc.
Today, Celmatix, the next-generation women’s health company, announced the initial findings of two landmark research studies that shed new light on biomarkers that are related to a woman’s fertility and her ovarian reserve.
Landmark strategic commercial collaboration expands the global footprint of the first-of-its-kind reproductive health test for women
Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women’s Health
Research collaboration aims to uncover new insights into ovarian biology and accelerate the development of personalized interventions in reproductive medicine and women’s health.
Celmatix announced that Richard Hofbauer has joined its executive team in the role of Chief Operating Officer (COO) and interim Chief Financial Officer (CFO).
This award represents the council’s largest life science investment in New York City this year.
Celmatix: The Fertilome Test is the First Multigene Panel Test for Women’s Risk of Reproductive Conditions Approved by the NY State Department of Health
Announced in January 2017, the Fertilome test has already been ordered for numerous women by reproductive specialists and OB-GYNs across the U.S.
Celmatix And Reproductive Medicine Associates Of New York Announce Landmark Study Correlating Optimal Hormone Stimulation With Embryo Quality
Celmatix, Inc. Release: Study Indicates Cystic Fibrosis Carrier Status In Females Not A Factor In IVF Success
Celmatix, Inc. Presents Study At American Society for Reproductive Medicine Annual Meeting Showing That Most Fertility Patients Would Benefit From Moving More Rapidly To IVF Treatment
Celmatix, Inc. Initiates Multi-Center Clinical Trial For Polaris, The World's First Data Fusion Platform For Maximizing Fertility